Mantle cell lymphoma trials in Greece

1 trial · From ClinicalTrials.gov, checked 14 November 2026. Ask the study team whether a trial fits you.

• Phase 1Taking people
  Dose Determining Study of EXS73565 in Participants With Relapsed or Refractory B-Cell Malignancies

  Where

  Athens, Patras, Thessaloniki

  Age

  18 years and over

  People

  85 worldwide

  Run by

  Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.

  See details and how to joinNCT06980116 · EU 2024-516869-36-00